Law Firms Urge Nektar Investors to Seek Lead Role in Securities Suit Over REZOLVE-AA Protocol Claims

Overview

• Competing plaintiff firms issued fresh notices Thursday and Friday urging Nektar shareholders to move by May 5, 2026 to serve as lead plaintiff.
• The lawsuits claim Nektar misled investors by failing to disclose that its REZOLVE-AA trial enrollment did not follow required instructions and protocol standards.
• Filings say those enrollment lapses likely hurt trial results and overstated the study’s integrity, making the company’s upbeat statements misleading.
• Nektar disclosed on December 16, 2025 that the Phase 2b trial missed statistical significance and cited inclusion of four ineligible patients, after which the stock fell about 7.8%.
• The case is in early stages with no class certified, so investors are not represented unless they retain counsel, and the chosen lead plaintiff will guide strategy and settlement talks.